Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Hlavní autoři: | , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
BMC
2019-07-01
|
Edice: | BMC Public Health |
Témata: | |
On-line přístup: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |